A Phase 1/2a Open-Label Study to Investigate the Safety of the Transplantation (by Injection) of Human Glial Restricted Progenitor Cells (hGRPs; Q-Cells®) Into Subjects With Amyotrophic Lateral Sclerosis (ALS): Assessment of Localized Therapeutic Activity by Blinded Observation and Lateral Transplantation (ALTA-BOLT)
Latest Information Update: 23 Aug 2023
At a glance
- Drugs Human glial restricted progenitor cells based therapeutics (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions; First in man
- Acronyms ALTA-BOLT
- Sponsors Q Therapeutics
- 17 Aug 2023 Planned End Date changed from 1 Dec 2024 to 1 Dec 2025.
- 17 Aug 2023 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2025.
- 17 Aug 2023 Planned initiation date changed from 1 Dec 2021 to 1 Mar 2024.